ProMIS Neurosciences Inc. (PMN) - Net Assets
Based on the latest financial reports, ProMIS Neurosciences Inc. (PMN) has net assets worth $9.19 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.46 Million) and total liabilities ($12.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PMN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.19 Million |
| % of Total Assets | 42.82% |
| Annual Growth Rate | 7.02% |
| 5-Year Change | N/A |
| 10-Year Change | 2648.13% |
| Growth Volatility | 7212.52 |
ProMIS Neurosciences Inc. - Net Assets Trend (2005–2024)
This chart illustrates how ProMIS Neurosciences Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore PMN total assets for the complete picture of this company's asset base.
Annual Net Assets for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual net assets of ProMIS Neurosciences Inc. from 2005 to 2024. For live valuation and market cap data, see PMN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $16.49 Million | +339.30% |
| 2023-12-31 | $3.75 Million | +305.68% |
| 2022-12-31 | $-1.82 Million | -125.50% |
| 2021-12-31 | $7.16 Million | +804.51% |
| 2020-12-31 | $-1.02 Million | -355.18% |
| 2019-12-31 | $398.12K | -65.57% |
| 2018-12-31 | $1.16 Million | -24.59% |
| 2017-12-31 | $1.53 Million | +2108.40% |
| 2016-12-31 | $69.43K | -88.43% |
| 2015-12-31 | $599.98K | +402.67% |
| 2013-12-31 | $-198.23K | +6.73% |
| 2012-12-31 | $-212.54K | +1.72% |
| 2011-12-31 | $-216.25K | -26827.64% |
| 2010-12-31 | $809.08 | -99.98% |
| 2009-12-31 | $4.67 Million | +19.86% |
| 2008-12-31 | $3.90 Million | -53.86% |
| 2007-12-31 | $8.45 Million | -30.74% |
| 2006-12-31 | $12.20 Million | +168.32% |
| 2005-12-31 | $4.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProMIS Neurosciences Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8885827046.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-371.18K | -2.25% |
| Other Components | $107.55 Million | 652.26% |
| Total Equity | $16.49 Million | 100.00% |
ProMIS Neurosciences Inc. Competitors by Market Cap
The table below lists competitors of ProMIS Neurosciences Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lantern Pharma Inc
NASDAQ:LTRN
|
$23.71 Million |
|
Nico Resources Ltd
AU:NC1
|
$23.71 Million |
|
RN2 Technologies Co. Ltd
KQ:148250
|
$23.72 Million |
|
Ntaw Holdings Ltd
AU:NTD
|
$23.73 Million |
|
Pantaflix AG
XETRA:PAL
|
$23.67 Million |
|
Longeveron LLC
NASDAQ:LGVN
|
$23.66 Million |
|
Amanah Leasing Public Company Limited
BK:AMANAH
|
$23.62 Million |
|
Star Paper Mills Limited
NSE:STARPAPER
|
$23.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProMIS Neurosciences Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,753,296 to 16,488,176, a change of 12,734,880 (339.3%).
- Net income of 2,778,873 contributed positively to equity growth.
- New share issuances of 27,847,771 increased equity.
- Other factors decreased equity by 17,891,764.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.78 Million | +16.85% |
| Share Issuances | $27.85 Million | +168.9% |
| Other Changes | $-17.89 Million | -108.51% |
| Total Change | $- | 339.30% |
Book Value vs Market Value Analysis
This analysis compares ProMIS Neurosciences Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.71x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $353.18 | $11.01 | x |
| 2006-12-31 | $576.11 | $11.01 | x |
| 2007-12-31 | $306.82 | $11.01 | x |
| 2008-12-31 | $139.24 | $11.01 | x |
| 2009-12-31 | $146.87 | $11.01 | x |
| 2010-12-31 | $0.02 | $11.01 | x |
| 2011-12-31 | $-6.33 | $11.01 | x |
| 2012-12-31 | $-5.62 | $11.01 | x |
| 2013-12-31 | $-4.90 | $11.01 | x |
| 2015-12-31 | $8.34 | $11.01 | x |
| 2016-12-31 | $0.61 | $11.01 | x |
| 2017-12-31 | $11.18 | $11.01 | x |
| 2018-12-31 | $7.25 | $11.01 | x |
| 2019-12-31 | $2.30 | $11.01 | x |
| 2020-12-31 | $-5.34 | $11.01 | x |
| 2021-12-31 | $30.93 | $11.01 | x |
| 2022-12-31 | $-6.08 | $11.01 | x |
| 2023-12-31 | $7.63 | $11.01 | x |
| 2024-12-31 | $15.58 | $11.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProMIS Neurosciences Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.85%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (16.85%) is above the historical average (-22697.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -37.12% | -5388.21% | 0.01x | 1.05x | $-2.14 Million |
| 2006 | -30.09% | -1668.80% | 0.02x | 1.05x | $-4.89 Million |
| 2007 | -82.69% | -1505.39% | 0.05x | 1.15x | $-7.83 Million |
| 2008 | -104.61% | -2105.59% | 0.04x | 1.12x | $-4.47 Million |
| 2009 | -102.00% | -2704.69% | 0.03x | 1.14x | $-5.23 Million |
| 2010 | -423529.54% | -278.43% | 951.17x | 1.60x | $-3.43 Million |
| 2011 | 0.00% | -2799.05% | 0.28x | 0.00x | $-2.53 Million |
| 2012 | 0.00% | -4505.49% | 0.15x | 0.00x | $-2.17 Million |
| 2013 | 0.00% | -1519.23% | 0.46x | 0.00x | $-2.02 Million |
| 2015 | -254.74% | -10639.79% | 0.01x | 1.92x | $-1.59 Million |
| 2016 | -3702.09% | -128390.21% | 0.00x | 13.94x | $-2.58 Million |
| 2017 | -312.21% | -60838.48% | 0.00x | 1.42x | $-4.94 Million |
| 2018 | -645.59% | -2140457.07% | 0.00x | 2.57x | $-7.58 Million |
| 2019 | -1857.79% | -615329.37% | 0.00x | 5.21x | $-7.44 Million |
| 2020 | 0.00% | -361814.19% | 0.00x | 0.00x | $-5.56 Million |
| 2021 | -134.93% | -118662.18% | 0.00x | 3.14x | $-10.37 Million |
| 2022 | 0.00% | -221930.57% | 0.00x | 0.00x | $-17.88 Million |
| 2023 | -466.42% | 0.00% | 0.00x | 3.63x | $-17.88 Million |
| 2024 | 16.85% | 0.00% | 0.00x | 1.15x | $1.13 Million |
Industry Comparison
This section compares ProMIS Neurosciences Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProMIS Neurosciences Inc. (PMN) | $9.19 Million | -37.12% | 1.34x | $23.70 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more